-
Transfusing children with sickle cell disease using blood group genotyping when the pool of Black donors is limited Transfusion (IF 2.9) Pub Date : 2024-03-18 Gabriel André Leiva-Torres, Maude Cigna, Jessica Constanzo-Yanez, Maryse St-Louis, Josée Perreault, Josée Lavoie, Geneviève Laflamme, Antoine Lewin, Yves Pastore, Nancy Robitaille
Red blood cell transfusion is an effective treatment for patients with sickle cell disease (SCD). Alloimmunization can occur after a single transfusion, limiting further usage of blood transfusion. It is recommended to match for the ABO, D, C, E, and K antigens to reduce risks of alloimmunization. However, availability of compatible blood units can be challenging for blood providers with a limited
-
Ethical considerations in the use of RhD‐positive blood products in trauma Transfusion (IF 2.9) Pub Date : 2024-03-16 Jay R. Malone
BackgroundPrehospital and early in‐hospital use of low titer group O whole blood (LTOWB) for life‐threatening bleeding has been independently associated with improved survival compared to component therapy. However, when RhD‐positive blood products are administered to RhD‐negative females of childbearing potential (FCP), there is a small future risk of hemolytic disease of the fetus and newborn (HDFN)
-
Managing blood product shortages: Unprecedented challenges require novel solutions Transfusion (IF 2.9) Pub Date : 2024-03-16 Jeremy W. Jacobs, Sheharyar Raza, Jennifer S. Woo
-
-
Reply Transfusion (IF 2.9) Pub Date : 2024-03-16 Evan G. Pivalizza, Maggie M. Swift, Jeffrey H. Fair
-
-
In response: Caution in prediction: Evaluating Zhang et al.'s approach to red blood cell transfusion risk Transfusion (IF 2.9) Pub Date : 2024-03-16 Sarah J. Power, Kenneth E. Stewart, Kenichi A. Tanaka, Amir L. Butt
-
Reply Transfusion (IF 2.9) Pub Date : 2024-03-16 Qiaoni Zhang, Yuchen Gao, Tianlong Wang, Zhiyuan Bo, Bingyang Ji
-
In response: Caution in extrapolating hypercoagulable viscoelastic coagulation test results to in vivo hemostasis Transfusion (IF 2.9) Pub Date : 2024-03-16 Amir L. Butt, Srikiran Ramarapu, Hiroki Kyo, Kenichi A. Tanaka
-
Evaluation of platelets componentized with the Reveos Automated Blood Processing System and stored for 7 days at room temperature in a non‐Di(2‐ethylhexyl) phthalate (DEHP) platelet pooling set Transfusion (IF 2.9) Pub Date : 2024-03-16 Kristin M. Reddoch‐Cardenas, Samantha L. Perez, Justin N. Ferdin, Michael A. Meledeo
BackgroundPlatelet concentrates (PCs) used for transfusion can be produced by apheresis or derived from whole blood (WB). The Reveos device is the first US Food and Drug Administration‐approved automated blood processing system that can produce PCs. In this work, we evaluated the quality and function of Reveos‐collected PCs stored for 7 days at room temperature.Study Design and MethodsWB was collected
-
A case of transfusion‐transmission Anaplasma phagocytophilum from leukoreduced red blood cells Transfusion (IF 2.9) Pub Date : 2024-03-16 Laura Tonnetti, Luis A. Marcos, Linda Mamone, Eric D. Spitzer, Matthew Jacob, Rebecca L. Townsend, Susan L. Stramer, Fay B. West
BackgroundAnaplasma phagocytophilum is a tick‐borne bacterium and the cause of human granulocytic anaplasmosis (HGA). Here, we report a case of transfusion‐transmitted (TT)‐HGA involving a leukoreduced (LR) red blood cell (RBC) unit.Case ReportA 64‐year‐old woman with gastric adenocarcinoma and multiple myeloma who received weekly blood transfusions developed persistent fevers, hypotension, and shortness
-
Continuing Medical Education Transfusion (IF 2.9) Pub Date : 2024-03-16
CME Editor: Julie Katz Karp, MD. Article Title: Protamine dosing and its impact in cardiac surgery transfusion practice – a retrospective bi-institutional analysis. Article Authors: Mondal S, Abuelkasem E, Vesselinov R, Henderson R, Choi S, Mousa A, Zaza K, Tanaka K. If you wish to receive credit for this activity, please refer to the website: https://www.wileyhealthlearning.com/trf Educational Objective:
-
A monthly roundup of key articles in other journals Transfusion (IF 2.9) Pub Date : 2024-03-15 Caitlin McOmish
-
Transfusion‐related errors and associated adverse reactions and blood product wastage as reported to the National Healthcare Safety Network Hemovigilance Module, 2014–2022 Transfusion (IF 2.9) Pub Date : 2024-03-13 Joel L. Chavez Ortiz, Isabel Griffin, Sophia V. Kazakova, Phylicia B. Stewart, Ian Kracalik, Sridhar V. Basavaraju
BackgroundTransfusion‐related errors are largely preventable but may lead to blood product wastage and adverse reactions, resulting in patient harm. In the United States, the incidence of transfusion‐related errors is poorly understood nationally. We used data from the National Healthcare Safety Network (NHSN) Hemovigilance Module to describe and quantify transfusion‐related errors, as well as associated
-
Identification of a novel O allele with c.777C>G on an ABO*O.01.02 background Transfusion (IF 2.9) Pub Date : 2024-03-12 Lin‐Nan Shao, Yi‐Cheng Yang, Yue‐Xin Xia, Chun‐Xiang Li, Shi‐Hang Zhou
CONFLICT OF INTEREST STATEMENT The authors have disclosed no conflicts of interest.
-
Tranexamic acid in trauma: After 3 hours from injury, when is it safe and effective to use again? Transfusion (IF 2.9) Pub Date : 2024-03-10 Christopher D. Barrett, Matthew D. Neal, Jonathan G. Schoenecker, Robert L. Medcalf, Paul S. Myles
Tranexamic acid (TXA) has proven mortality benefit if used early after traumatic injury, likely related to a combination of bleeding reduction and other non‐bleeding effects. If TXA is given more than 3 h after traumatic injury, there is a significant and paradoxical increased risk of death due to bleeding. TXA has level 1 evidence for use as a bleeding reduction agent in isolated orthopedic operations
-
Comparable bacterial growth in platelet concentrates suspended in plasma and platelet additive solution and improved detection of bacterial contamination using a new generation automated culture system Transfusion (IF 2.9) Pub Date : 2024-03-08 Yuntong Kou, Dilini Kumaran, Anita Howell, Sandra Ramirez‐Arcos
BackgroundMicrobial screening of platelet concentrates (PC) with automated culture methods is widely implemented to reduce septic transfusion reactions. Herein, detection of bacterial contamination in PC was compared between units prepared in plasma and a mix of plasma and platelet additive solution (PAS) and between the BACT/ALERT 3D and next generation BACT/ALERT VIRTUO systems.Study Design/MethodsDouble
-
Identification of a novel A allele with a nucleotide deletion c.198delG in the ABO gene associated with Ael phenotype Transfusion (IF 2.9) Pub Date : 2024-03-06 Haixiao Zheng, Chan Peng, Min Wang, Qinhan Hong, Lin Hua
CONFLICT OF INTEREST STATEMENT The authors have disclosed no conflicts of interest.
-
The first two years of the use of low titer group O whole blood during French Military overseas operations: A retrospective study Transfusion (IF 2.9) Pub Date : 2024-03-05 Jean‐Clément Riff, Olivier Duranteau, Sylvain Ausset, Pierre Pasquier, Estelle Fleuriot, Vanina Corominas, Mathieu Boutonnet
BackgroundOn the battlefield, hemorrhage is the main cause of potentially preventable death. To reduce mortality due to hemorrhagic injuries, the French Military Medical Service (FMMS) has deployed low titer group O whole blood (LTOWB) since June 2021 during operation BARKHANE in the Sahel–Saharan strip. Questions persist regarding the circumstances under which the FMMS employs LTOWB during overseas
-
Analyzing and modeling massive transfusion strategies and the role of fibrinogen—How much is the patient actually receiving? Transfusion (IF 2.9) Pub Date : 2024-03-04 Nadia M. Keltner, Melissa M. Cushing, Thorsten Haas, Philip C. Spinella
BackgroundHemorrhage is a leading cause of preventable death in trauma, cardiac surgery, liver transplant, and childbirth. While emphasis on protocolization and ratio of blood product transfusion improves ability to treat hemorrhage rapidly, tools to facilitate understanding of the overall content of a specific transfusion strategy are lacking. Medical modeling can provide insights into where deficits
-
Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy Transfusion (IF 2.9) Pub Date : 2024-03-01 R. Christopher Chase, Andree H. Koop, Marwan Shaikh, Robin J. Imperial, Denise M. Harnois, Nicole M. Loo, Jennifer J. O'Brien
IntroductionThis case describes passenger lymphocyte syndrome (PLS) generating human platelet antigen 1a (HPA‐1a) alloantibodies against the recipient's platelets after liver transplant. Given the rarity of PLS, especially in liver transplant with HPA‐1a alloantibodies, disease course and management options are poorly described.MethodsThe patient had cirrhosis secondary to nonalcoholic steatohepatitis
-
Estimated median density identifies donor age and sex differences in red blood cell biological age Transfusion (IF 2.9) Pub Date : 2024-02-29 Olga Mykhailova, Mackenzie Brandon‐Coatham, Kiarra Durand, Carly Olafson, April Xu, Qi‐Long Yi, Tamir Kanias, Jason P. Acker
BackgroundDonors possess heterogeneous red cell concentrates (RCCs) in terms of the biological age of their red blood cells (RBCs) as a direct result of various donor‐dependent factors influencing rates of erythropoiesis. This study aimed to estimate the median biological age of RBCs in RCCs based on donor age and sex to investigate inherent differences in blood products' biological ages over hypothermic
-
Significant changes to AABB Standards: Updated quality system essentials Transfusion (IF 2.9) Pub Date : 2024-02-29 Patrick Ooley, Christopher Bocquet
In the late 1990s, AABB joined many other accrediting organizations in embracing a quality system approach to setting standards. This change, seen at the time as the new era of standards-setting, was marked by a shift from error detection to error prevention as the main emphasis. AABB termed the framework for this approach “quality system essentials (QSEs).” These QSEs were incorporated into all eight
-
Radiofrequency identification tracking system (RFID) significantly improves blood bank inventory management and decreases staff work effort Transfusion (IF 2.9) Pub Date : 2024-02-29 Antoine Tavares da Souza, Jennylyn Flores, Loevette Millendez, Marites Filio, Yunchuan Delores Mo, Cyril Jacquot, Meghan Delaney
BackgroundBefore implementation of the radio frequency identification (RFID) system, there was a high loss rate of 4.0%–4.3% of red blood cell (RBC) units every year expiring on the shelf in our transfusion service laboratory. We introduced RFID technology to improve inventory management and the burden of work on the staff. The goal of this study was to evaluate the impact of RFID technology on the
-
Collection efficiency and safety of large‐volume leukapheresis for the manufacturing of tisagenlecleucel Transfusion (IF 2.9) Pub Date : 2024-02-29 Wataru Kitamura, Tomohiro Urata, Keiko Fujii, Takuya Fukumi, Kazuhiro Ikeuchi, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda, Nobuharu Fujii
BackgroundIn patients with relapsed or refractory B cell acute lymphoblastic leukemia or B cell non‐Hodgkin lymphoma (r/r B‐ALL/B‐NHL) with low CD3+ cells in the peripheral blood (PB), sufficient CD3+ cell yield in a single day may not be obtained with normal‐volume leukapheresis (NVL). Large‐volume leukapheresis (LVL) refers to the processing of more than three times the total blood volume (TBV) in
-
Maternal and child life years gained by transfusing low titer group O whole blood in trauma: A computer simulation Transfusion (IF 2.9) Pub Date : 2024-02-26 Mark H. Yazer, Christine Leeper, Philip C. Spinella, Stephen P. Emery, Sarah Horvath, Jansen N. Seheult
BackgroundUsing low titer group O whole blood (LTOWB) is increasingly popular for resuscitating trauma patients. LTOWB is often RhD‐positive, which might cause D‐alloimmunization and hemolytic disease of the fetus and newborn (HDFN) if transfused to RhD‐negative females of childbearing potential (FCP). This simulation determined the number of life years gained by the FCP and her future children if
-
Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation Transfusion (IF 2.9) Pub Date : 2024-02-26 Esa Jantunen, Antti Turunen, Ville Varmavuo, Anu Partanen
Plerixafor (PLER), a reversible antagonist of the CXC chemokine receptor type 4, has been in clinical use for mobilization of blood grafts for autologous hematopoietic cell transplantation (AHCT) for about 15 years. Initially PLER was investigated in placebo‐controlled trials with the granulocyte colony‐stimulating factor (G‐CSF) filgrastim. It has also been used in combination with chemotherapy plus
-
Functional effects of an African glucose‐6‐phosphate dehydrogenase (G6PD) polymorphism (Val68Met) on red blood cell hemolytic propensity and post‐transfusion recovery Transfusion (IF 2.9) Pub Date : 2024-02-24 Ling Wang, Elizabeth R. Rochon, Sebastien Gingras, Benjamin E. Zuchelkowski, Derek J. Sinchar, Elimira Alipour, Julie A. Reisz, Minying Yang, Grier P. Page, Tamir Kanias, Darrell J. Triulzi, Janet S. Lee, Daniel B. Kim‐Shapiro, Angelo D'Alessandro, Mark T. Gladwin
BackgroundDonor genetic variation is associated with red blood cell (RBC) storage integrity and post‐transfusion recovery. Our previous large‐scale genome‐wide association study demonstrated that the African G6PD deficient A‐ variant (rs1050828, Val68Met) is associated with higher oxidative hemolysis after cold storage. Despite a high prevalence of X‐linked G6PD mutation in African American population
-
Autoantibody profiles in intravenous immunoglobulin preparations: A possible cause of mistaken autoimmunity diagnosis Transfusion (IF 2.9) Pub Date : 2024-02-24 Tatsuki Miyamoto, Yuki Fukunaga, Atsushi Ogasawara, Ai Munakata, Katsushi Murai
BackgroundIntravenous immunoglobulins (IVIgs) derived from the pooled plasma of thousands of donors contain numerous types of IgG molecules, including autoantibodies commonly used to diagnose autoimmunity. While these autoantibodies can cause misinterpretation of serological tests for IVIg recipients, their profiles in IVIg preparations are not fully understood.Study Design and MethodsUsing binding‐capability
-
The Tägerwilen II report: Recommendations from the NATO Prehospital Care Improvement Initiative Task Force Transfusion (IF 2.9) Pub Date : 2024-02-24 Christian Medby, Colleen Forestier, Benjamin Ingram, Duncan Parkhouse, Michael Alvarez‐Brueckmann, Alexander Faas
BackgroundThe Committee of the Chiefs of Military Medical Services (COMEDS) initiated the Prehospital Care Improvement Initiative Task Force (PHCII TF) to advise on how to improve prehospital care within NATO nations. The Task Force consisted of the NATO Military Health Care Working Group and its subordinated expert panels, including the Blood Panel, the Emergency Medicine Panel and the Special Operations
-
Classification of posttransfusion adverse events using a publicly available artificial intelligence system Transfusion (IF 2.9) Pub Date : 2024-02-24 Mark K. Fung, James P. AuBuchon, Laura D. Stephens
BackgroundCorrect classification of transfusion reactions is important not only for effective patient care and donor management but also for accurate tracking of events in hemovigilance systems. We compared the ability of a generative artificial intelligence (AI) system to correctly diagnose hypothetical clinical situations as transfusion reactions in comparison to previous studies reporting the accuracy
-
Generation of human antibodies targeting human platelet antigen (HPA)‐1a Transfusion (IF 2.9) Pub Date : 2024-02-24 Janita J. Oosterhoff, Federica Linty, Remco Visser, Thijs de Vos, Suzanne Hofstede‐van Egmond, Miranda van de Weerd, Leendert Porcelijn, Masja de Haas, Ellen van der Schoot, Gestur Vidarsson
BackgroundFetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition during pregnancy, which can lead to thrombocytopenia and a bleeding tendency with intracranial hemorrhage (ICH) being the most concerning complication in the fetus or neonate. An incompatibility between human platelet antigen (HPA)‐1a accounts for the majority of FNAIT cases. Binding of HPA‐1a‐specific alloantibodies to
-
Blood donation and migraine relief: A national population cohort study in Denmark Transfusion (IF 2.9) Pub Date : 2024-02-24 Olafur B. Davidsson, Klaus Rostgaard, Mona A. Chalmer, Lisette J. A. Kogelman, Bitten Aagaard, Thorsten Brodersen, Mie Topholm Bruun, Christina Mikkelsen, Susan Mikkelsen, Mette Nyegaard, Ole Birger Pedersen, Henrik Ullum, Erik Sørensen, Sisse Rye Ostrowski, Christian Erikstrup, Thomas Folkmann Hansen, Henrik Hjalgrim
IntroductionMigraine is a prevalent neurological headache disorder. Due to challenges associated with finding effective treatment, many individuals with migraine feel compelled to explore alternative treatment strategies, such as blood donation, hypothesized to provide migraine relief.MethodsThrough logistic, Poisson, and Cox regression methods, we examined the links between migraine and blood donation
-
-
-
Infectious disease agents and their potential threat to transfusion safety (an update to the 2009 Transfusion supplement) Transfusion (IF 2.9) Pub Date : 2024-02-23 L. M. Katz, Roger Y. Dodd, Paula Saa, J. B. Gorlin, K. Palmer, F. B. Hollinger, S. L. Stramer
-
-
-
-
-
-
Donor complication rates in whole blood, plasma and platelet donors: Age versus experience Transfusion (IF 2.9) Pub Date : 2024-02-22 Yared Paalvast, Niubel Díaz Padilla, Sanne Bruijns, Johanna Wiersum‐Osselton, Ties Molenaar
BackgroundMany blood banks use upper age limits for donors out of concern for a higher donor complication rate in older donors. Experienced donors are known to have lower donor complication rates, and older donors are often more experienced, confounding the effect of age on donor complication rate.Study Design and MethodsWe studied donor complication rates in whole blood, plasma, and plateletpheresis
-
When do benefits turn to risks? Impact of a 900 mL whole blood donation on Special Forces performance Transfusion (IF 2.9) Pub Date : 2024-02-22 Julie Degueldre, E. Dessy, F. T'Sas, E. Keesebilck, V. Deneys
BackgroundSpecial Forces (SF) teams operate in remote environments with limited medical support. As a result, they may need to rely on buddy transfusions to treat bleeding teammates. Considering that 450 mL has no direct impact on their combat performances, it might be tempting to take more blood from a compatible donor to save a hemorrhaging teammate. This study investigates the effect of a 900 mL
-
Iatrogenic blood loss from phlebotomy during adult extracorporeal membrane oxygenation: A retrospective cohort study Transfusion (IF 2.9) Pub Date : 2024-02-22 Michael Mazzeffi, David Miller, Angela Wang, Venkat Kothandaraman, Dustin Money, Brian Clouse, Akram M. Zaaqoq, Nicholas Teman
Adult extracorporeal membrane oxygenation (ECMO) patients are at high risk for allogeneic blood transfusion. Few studies have characterized iatrogenic blood loss from phlebotomy in adult ECMO patients. We hypothesized that iatrogenic phlebotomy would be a significant source of blood loss during ECMO.
-
A monthly roundup of key articles in other journals Transfusion (IF 2.9) Pub Date : 2024-02-21 Caitlin McOmish
-
-
-
Re‐scanning the transfusion‐transmitted disease horizon Transfusion (IF 2.9) Pub Date : 2024-02-21 Richard M. Kaufman
-
In Response: Getting the measure of hepatitis A virus (HAV): A better understanding of the RNA content of HAV reference material and blood donations Transfusion (IF 2.9) Pub Date : 2024-02-21 Sally A. Baylis, Michael Chudy, Johannes Blümel
-
Donors with repeated blood product discards for filtration problems, clots or hemolysis: Causes and follow‐up Transfusion (IF 2.9) Pub Date : 2024-02-21 Niubel Díaz Padilla, Johanna C Wiersum‐Osselton, Shahryar Ghasemi Nezjad, Gitta Dijkshoorn, Fernando Gonzalez‐Garcia, Vĕra M. J. Novotny
IntroductionSanquin donor medicine department is informed when donations or their components are rejected. This can occur isolated or frequently. It is undesirable because the donations cannot be used and there may be an underlying medical cause. Based on regional approaches, a uniform procedure was developed.MethodsInformation about whole blood, plasma‐ plateletpheresis donations from which one or
-
Characteristics of blood banking/transfusion medicine fellows in the United States, 2013–2021: Lessons learned from the Transfusion Medicine In‐Service Examination (TMISE) practice survey Transfusion (IF 2.9) Pub Date : 2024-02-21 Matthew S. Karafin, Yvette C. Tanhehco, Justin D. Kreuter
-
-
The 2023 AABB international guidelines for red blood cell transfusions: What is new? Transfusion (IF 2.9) Pub Date : 2024-02-21 Monica B. Pagano, Simon J. Stanworth, Stacey Valentine, Ryan Metcalf, Erica M. Wood, Katerina Pavenski, Jill Cholette, Cynthia So‐Osman, Jeffrey L. Carson
-
Biochemical characterization of Jr(a−) blood type‐related ABCG2 variants: Arg147Trp and Ser572Arg disrupt the plasma membrane localization of ABCG2 Transfusion (IF 2.9) Pub Date : 2024-02-21 Yu Toyoda, Hirotaka Matsuo, Mitsunobu Tanaka, Blanka Stiburkova, Tappei Takada
-
Intentional transfusion of expired blood products Transfusion (IF 2.9) Pub Date : 2024-02-21 Brian C. Riley, Lynn G. Stansbury, Daniel J. Roubik, Rida A. Hasan, John R. Hess
CONFLICT OF INTEREST STATEMENT JRH is the inventor of the AS-7 8-week RBC additive solution and a consultant to Hemerus, LLC, licensee of the technology. LGS is married to JRH.
-
Traumatic subcutaneous emphysema following blood donation: A case report Transfusion (IF 2.9) Pub Date : 2024-02-21 Pallavi Singh, Revathy Nair K, Akshay Batra, Satyendra Narayan Singh
Subcutaneous emphysema is a condition where air becomes trapped under the skin, typically resulting from surgery or skin trauma. It is mostly localized and its occurrence in blood donors is exceedingly rare. Phlebotomy poses minimal risk of subcutaneous emphysema, but procedural errors may lead to such complications.
-
A novel ABCG2 variant causing Jr(a−) phenotype Transfusion (IF 2.9) Pub Date : 2024-02-15 Soon Sung Kwon, Yeo Eun Yun, Na Hyeong Kim, Eun Jung Suh, Soo-Kyung Kim, Sinyoung Kim
CONFLICT OF INTEREST STATEMENT The authors have disclosed no conflicts of interest.
-
Blood consumption in the Role 2 setting: A Department of Defense Trauma Registry analysis Transfusion (IF 2.9) Pub Date : 2024-02-15 Kelly K. McWhirter, Michael D. April, Andrew D. Fisher, Franklin L. Wright, Julie A. Rizzo, Jason B. Corley, Todd M. Getz, Steven G. Schauer
The Role 2 setting represents the most far-forward military treatment facility with limited surgical and holding capabilities. There are limited data to guide recommendations on blood product utilization at the Role 2. We describe the consumption of blood products in this setting.
-
Transfusion medicine history illustrated: Lawrence Bruce‐Robertson's “syringe and cannula method” set used for blood transfusion in the management of casualties in the First World War, 1914–1918 Transfusion (IF 2.9) Pub Date : 2024-02-20 Andrew N. Beckett, Peter H. Pinkerton
-
Performance of far forward iceless blood storage containers in controlled cold environments Transfusion (IF 2.9) Pub Date : 2024-02-16 Antoine Vuong, Clément Derkenne, Stéphane Travers, Olivier Javaudin, Benoît Clavier, Christophe Martinaud, Pierre Pasquier
The Golden Hour Box (GHB), an iceless blood container designed for transfusion closest to the point of injury, is used by military medical teams in remote damage control resuscitation. While its performance is well-established in hot environments, it remains underexplored in cold conditions, a significant consideration in emerging global conflict zones.